Biomarkers in the lung cancer diagnosis: A clinical perspective

Neoplasma

Volumn 59, Issue 5, 2012, Pages 500-507

  Li, X ^a   Asmitananda, T ^a   Gao, L ^a   Gai, D ^a   Song, Z ^a   Zhang, Y ^a   Ren, H ^a   Yang, T ^a   Chen, T ^a   Chen, M ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biomarker; Combination; Diagnosis; Lung cancer; Sensitivity; Specificity

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; FERRITIN; NEURON SPECIFIC ENOLASE; ANTIGEN CYFRA21.1; CA 125 ANTIGEN; ENOLASE; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG DISEASE; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; ADENOCARCINOMA; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; ELECTROCHEMISTRY; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COHORT STUDIES; ELECTROCHEMISTRY; FEMALE; HUMANS; KERATIN-19; LUNG; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; ROC CURVE; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84866761739     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_064     Document Type: Article

References (53)

1. Incidence and prevalence of cancer both in Europe and in the wider world. Editorial. Eur J Cancer Care (Engl), 17: 515, 2008. http://dx.doi.org/10.1111/j.1365-2354.2008.01052.x
2. WU J M, DU Y X. Summary of papers and research recommendations presented at the International Symposium on Lifestyle Factors and Human Lung Cancer, Guangzhou, China. Lung Cancer, 14 Suppl 1: S223-34, 1996. http://dx.doi.org/10.1016/S0169-5002(96)90225-1
3. LIN H H, MURRAY M, COHEN T, COLIJN C, EZZATI M. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet, 372: 1473-83, 2008. http://dx.doi.org/10.1016/S0140-6736(08)61345-8
4. HUANG GJ, MAO YS, ZHANG DC, SUN KL, HE J, et al. Current status and future directions of surgery for lung cancer in China. Chin Med J (Engl), 120: 619-21, 2007.
5. DORIA-ROSE VP, MARCUS PM, SZABO E, TOCKMAN MS, MELAMED MR, et al. C. Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer, 115: 5007-17, 2009. http://dx.doi.org/10.1002/cncr.24545
6. EDEY AJ, HANSELL DM. CT lung cancer screening in the UK. Br J Radiol, 82: 529-31, 2009. http://dx.doi.org/10.1259/bjr/17503608
7. MONTUENGA LM, PIO R. Current challenges in lung cancer early detection biomarkers. Eur J Cancer, 45 Suppl 1: 377-8, 2009. http://dx.doi.org/10.1016/S0959-8049(09)70055-3
8. SCOTT A, SALGIA R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med, 2: 577-586, 2008. http://dx.doi.org/10.2217/17520363.2.6.577
9. HIRSCHOWITZ EA. Biomarkers for lung cancer screening: interpretation and implications of an early negative advanced validation study. Am J Respir Crit Care Med, 179: 1-2, 2009. http://dx.doi.org/10.1164/rccm.200809-1395ED
10. GOMEZ-ROCA C, RAYNAUD CM, PENAULT-LLORCA F, MERCIER O, COMMO F, et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol, 4: 1212-20, 2009. http://dx.doi.org/10.1097/JTO.0b013e3181b44321
11. SUNG HJ, CHO JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep, 41: 615-25, 2008. http://dx.doi.org/10.5483/BMBRep.2008.41.9.615
12. GREENBERG AK, LEE MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med, 13: 249-55, 2007. http://dx.doi.org/10.1097/MCP.0b013e32819f8f06
13. EPSTEIN SP, CHEN D, ASBELL PA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther, 25: 415-24, 2009. http://dx.doi.org/10.1089/jop.2008.0140
14. REINER AP, ARAGAKI AK, GRAY SL, WACTAWSKIWENDE J, CAULEY JA, et al. Inflammation and thrombosis biomarkers and incident frailty in postmenopausal women. Am J Med, 122: 947-54, 2009. http://dx.doi.org/10.1016/j.amjmed.2009.04.016
15. RIZVI AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci, 338: 310-8, 2009. http://dx.doi.org/10.1097/MAJ.0b013e3181a4158c
16. GOLD P, SHUSTER J, FREEDMAN SO. Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer, 42: 1399-405, 1978. http://dx.doi.org/10.1002/1097-0142(197809)42:3+1399::AIDCNCR28204208033.0.CO;2-P
17. JAPINK D, LEERS MP, SOSEF MN, NAP M. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer. Anticancer Res, 29: 3245-51, 2009.
18. CORREA-GALLEGO C, WARSHAW AL, FERNANDEZDEL CC. Fluid CEA in IPMNs: A useful test or the flip of a coin? Am J Gastroenterol, 104: 796-7, 2009. http://dx.doi.org/10.1038/ajg.2008.158
19. SREENARASIMHAIAH J, LARA LF, JAZRAWI SF, BARNETT CC, TANG SJ. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detec tion of mucin producing or malignant cysts. JOP, 10: 163-8, 2009.
20. SAJID KM, PARVEEN R, DURRE S, CHAOUACHI K, NAEEM A, et al. Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers. J Pak Med Assoc, 57: 595-9, 2007.
21. SONG MK, CHUNG JS, SEOL YM, SHIN HJ, CHOI YJ, et al. Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma. Korean J Intern Med, 24: 368-73, 2009. http://dx.doi.org/10.3904/kjim.2009.24.4.368
22. LORENZI M, LORENZI B, VERNILLO R. Serum ferritin in colorectal cancer patients and its prognostic evaluation. Int J Biol Markers, 21: 235-41, 2006.
23. SINGH KJ, SINGH SK, SURI A, VIJJAN V, GOSWAMI AK, et al. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage. Indian J Cancer, 42: 197-200, 2005.
24. AULBERT E, STEFFENS O. [Serum ferritin-a tumor marker in malignant lymphomas?]. Onkologie, 13: 102-8, 1990. http://dx.doi.org/10.1159/000216735
25. LI F, KISHIDA T, KOBAYASHI M. Serum iron and ferritin levels in patients with colorectal cancer in relation to the size, site, and disease stage of cancer. J Gastroenterol, 34: 195-9, 1999. http://dx.doi.org/10.1007/s005350050243
26. AULBERT E, SCHMIDT CG. Ferritin--a tumor marker in myeloid leukemia. Cancer Detect Prev, 8: 297-302, 1985.
27. ARIYOSHI Y, KUWABARA M. [Clinical significance of serum NSE assay as a tumor marker]. Nihon Rinsho, 48 Suppl: 1035-7, 1990.
28. SATOH H, ISHIKAWA H, KURISHIMA K, YAMASHITA Y T, OHTSUKA M, et al. Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep, 9: 581-3, 2002.
29. EBERT W, MULEY T, TRAINER C, DIENEMANN H, DRINGS P. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Anticancer Res, 22: 1083-9, 2002.
30. SHIBAYAMA T, UEOKA H, NISHII K, KIURA K, TABATA M, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 32: 61-9, 2001. http://dx.doi.org/10.1016/S0169-5002(00)00205-1
31. JORGENSEN LG, OSTERLIND K, GENOLLA J, GOMM SA, HERNANDEZ JR, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer, 74: 463-7, 1996. http://dx.doi.org/10.1038/bjc.1996.383
32. JORGENSEN LG, OSTERLIND K, HANSEN HH, COOPER EH. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC). Br J Cancer, 70: 759-61, 1994. http://dx.doi.org/10.1038/bjc.1994.391
33. JORGENSEN LG, OSTERLIND K, HANSEN HH, COOPER EH. Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). Br J Cancer, 66: 594-8, 1992. http://dx.doi.org/10.1038/bjc.1992.320
34. KOPROWSKI H, STEPLEWSKI Z, MITCHELL K, HERLYN M, HERLYN D, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet, 5: 957-71, 1979. http://dx.doi.org/10.1007/BF01542654
35. WASAN H S, SPRINGETT GM, CHODKIEWICZ C, WONG R, MAUREL J, et al. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer, 101: 1162-7, 2009. http://dx.doi.org/10.1038/sj.bjc.6605243
36. VORMITTAG L, GLEISS A, SCHEITHAUER W, LANG F, LAENGLE F, et al. Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer. Oncology, 77: 140-6, 2009. http://dx.doi.org/10.1159/000229754
37. KOOM W S, SEONG J, KIM YB, PYUN H O, SONG SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys, 73: 1148-54, 2009. http://dx.doi.org/10.1016/j.ijrobp.2008.06.1483
38. ATKINS CD. CA 19-9 and Lewis antigens in pancreatic cancer. J Clin Oncol, 27: 2572-3; author reply 2573, 2009. http://dx.doi.org/10.1200/JCO.2009.21.8198
39. PEZZILLI R, CASADEI R, CALCULLI L, SANTINI D, MORSELLI-LABATE AM. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary. Dig Liver Dis, 42: 73-4. http://dx.doi.org/10.1016/j.dld.2009.04.015
40. YAMAMOTO S, KOBAYASHI S, TANAKA M, AKIMOTO T, TAKASAKI Y. [Serum CA 19-9 levels in rheumatic diseases with interstitial pneumonia]. Nihon Rinsho Meneki Gakkai Kaishi, 19: 128-35, 1996. http://dx.doi.org/10.2177/jsci.19.128
41. OKINO T, YAMADORI I, OGINO T, MIKI H, HIRAKAWA E, et al. [An autopsied case of idiopathic interstitial pneumonia, showing a remarkably elevated serum level of CA 19-9]. Gan No Rinsho, 35: 69-73, 1989.
42. BUNGO M, YAMAJI Y, FUTAMI H, SHIOTANI T, IRINO S, et al. [Case of idiopathic interstitial pneumonia with marked increase of serum CA-19-9]. Nihon Kyobu Shikkan Gakkai Zasshi, 26: 185-9, 1988.
43. DONACH M, YU Y, ARTIOLI G, BANNA G, FENG W, et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biology, 31: 209-15, 2010. http://dx.doi.org/10.1007/s13277-010-0032-x
44. KIM HS, KIM JW, CHO JY, CHUNG HH, PARK NH, et al. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI. Eur J Surg Oncol, 35: 870-6, 2009. http://dx.doi.org/10.1016/j.ejso.2009.01.005
45. NISMAN B, YUTKIN V, PERETZ T, SHAPIRO A, BARAK V, et al. The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot study. Anticancer Res, 29: 4281-5, 2009.
46. MU X, GAO Z, YE R. [Correlation between Changes in Serum Level of CEA and CYFRA 21-1 and Objective Response of Chemotherapy.]. Zhongguo Fei Ai Za Zhi, 12: 1051-4, 2009.
47. KOSACKA M, JANKOWSKA R. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer. Pol Arch Med Wewn, 119: 33-7, 2009.
48. HOLDENRIEDER S, VON PAWEL J, DANKELMANN E, DUELL T, FADER L, et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer, 63: 128-35, 2009. http://dx.doi.org/10.1016/j.lungcan.2008.05.001
49. CHMURA A, WOJCIESZEK A, MROCHEM J, WALASZEKGRUSZKA A, DEJA R, et al. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma]. Ginekol Pol, 80: 361-6, 2009.
50. AL-SHAGAHIN H, ALKOTYFAN K, MULLER HH, SESTERHENN AM, and WERNER JA. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Anticancer Res, 29: 3421-5, 2009.
51. CHEN F, LUO X, ZHANG J, LU Y, LUO R. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Med Oncol, 27: 950-7. http://dx.doi.org/10.1007/s12032-009-9315-8
52. DABROWSKA M, GRUBEK-JAWORSKA H, DOMAGALAKULAWIK J, BARTOSZEWICZ Z, KONDRACKA A, et al. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer]. Pol Arch Med Wewn, 111: 659-65, 2004.
53. MOLINA R, FILELLA X, AUGE J M, FUENTES R, BOVER I, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol, 24: 209-18, 2003. http://dx.doi.org/10.1159/000074432